Apogee Therapeutics, Inc. ranks fourth on the list of 11 Best Future Stocks to Buy Now. The company, listed on NASDAQ as APGE, is a biotech firm developing antibody-based therapies for inflammatory conditions like atopic dermatitis and asthma, aiming to improve efficacy and dosing intervals.

In July 2025, Apogee Therapeutics reported positive 16-week results from its Phase 2 APEX trial of APG777, an anti-IL-13 antibody for atopic dermatitis. The data showed strong efficacy and safety, positioning APG777 as a potential best-in-class therapy with differentiated dosing advantages.

The company’s pipeline includes APG990, which demonstrated promising pharmacokinetics in Phase 1 trials, suggesting it could be administered every three to six months. This reflects Apogee Therapeutics’ strategy to provide long-acting, effective treatments for chronic inflammatory diseases.

While Google (GOOGL) has investment potential, some AI stocks offer greater upside and less downside risk. For a potentially undervalued AI stock with benefits from Trump-era tariffs, check out the report on the best short-term AI stock. No disclosures were made in the article.

Read more at Yahoo Finance: Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug